HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell lung cancer to pemetrexed through a HDAC2/miR-130a-3p-dependent mechanism

BACKGROUND: Histone deacetylases (HDAC) contribute to oncogenic program, pointing to their inhibitors as a potential strategy against cancers. We, thus, studied the mechanism of HDAC inhibitor ITF2357 in resistance of mutant (mut)-KRAS non-small cell lung cancer (NSCLC) to pemetrexed (Pem). METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Jian, Xu, Fei, Bai, Wei, Zhao, Tiantian, Hong, Junbo, Zuo, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930237/
https://www.ncbi.nlm.nih.gov/pubmed/36793108
http://dx.doi.org/10.1186/s12967-023-03973-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930237/
https://www.ncbi.nlm.nih.gov/pubmed/36793108
http://dx.doi.org/10.1186/s12967-023-03973-3

Ejemplares similares